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ABSTRACT: 
Fixed drug eruption (FDE) is common type of drug eruption seen in skin clinics. FDE usually occurs within 
hours of administration of the offending agent. Most commonly implicated are sulphonamides, salicylates, 
oxyphenbutazones, tetracycline, dapsone, chlordiazepoxide, barbiturates, phenolphthalein, morphine, codeine, 
quinine and derivatives, phenacetin, erythromycin, griseofulvin, mebendazole, meprobamate etc. We hereby 
report a case of fixed drug eruption on glans penis due to metronidazole, a nitroimidazole-derivative clinically 
indicated in trichomoniasis, amebiasis, giardiasis, anaerobic and mixed antibacterial infections. A patient 
administered metronidazole IV developed erythematous superficial non-tender ulceration over the glans penis 
on the second day of treatment with Inj. Metronidazole. A provisional diagnosis of metronidazole induced fixed 
drug eruption was made, metronidazole inj. was stopped and the patient was managed with Tab. Prednisolone 
30mg/day tapered over 10 days and Fusidic acid+Betamethasone cream.  
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INTRODUCTION: 
 
 A drug-induced reaction should be considered in any patient who is taking medications and who suddenly 
develops a symmetric cutaneous eruption.
 [1] Although the true incidence of adverse drug reactions (ADRs) is 
difficult to quantify, there is abundant evidence that cutaneous drug reactions (CDRs) are among the most 
frequent adverse events in patients receiving drug therapy.
 [2] Among all hospitalized patients, the incidence of 
CDRs has been found to range from 1 to 3%. 
[3, 4]  
 
Fixed drug eruption (FDE) is common type of drug eruption seen in skin clinics. FDE represents a unique CDR 
pattern characterized by skin lesion(s) that recur at the same anatomic site(s) upon repeated exposures to an 
offending agent. Most commonly, the skin lesion is a dusky erythematous macule and is usually found on the 
extremities, lips, genitalia and perianal areas, although any skin or mucosal surface may be involved. The skin 
lesions may be associated with a burning sensation and may be present in multiple numbers or progress to the 
development of central vesicles and bullae, particularly after the repeated use of an agent.
 [2] Persistent 
hyperpigmentation at the site of the lesion is normally seen after healing. Cross-sensitivity may occur with 
structurally similar drugs. The offending drug is thought to function as a hapten that preferentially binds to basal 
keratinocytes, thereby releasing lymphokines and antibodies thus damaging the basal cell layer.
 [5] The skin 
findings may be associated with nonspecific constitutional symptoms, including fever, malaise, nausea, and 
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are sulphonamides, salicylates, oxyphenbutazones, tetracycline, dapsone, chlordiazepoxide, barbiturates, 
phenolphtheline, morphine, codiene, quinine and derivatives, phenacetin, erythromycin, griseofulvin, 
mebendazole, meprobamate etc.
 [6,7,8] Certain medications also appear to have a tendency for certain anatomic 
locations (e.g., tetracyclines: genitalia). Many drugs such as dapsone, griseofulvin, erythromycin etc. are 
commonly used but FDE occurs rarely.
 [9]   Most commonly involved site of FDEs is glans penis. 
[8]   
 
We report a case of fixed drug eruption (FDE) due to metronidazole. We also carried out the causality and 
severity assessment associated adverse drug reactions (ADR) as per the Naranjo algorithm 
[10], Hartwig scale 
[11] 
and Modified Schumock and Thornton 
[12] scales respectively.  
 
METHOD:  
 
The case was detected in the Dermatology department following referral from the inpatient department of 
Surgery and subsequently treated by dermatology department. The case was also informed to the Department of 
Pharmacology by a Senior Resident Doctor of Dermatology Department. 
 
CASE REPORT: 
 
Metronidazole is a synthetic, nitroimidazole-derivative clinically indicated in trichomoniasis, amebiasis, 
giardiasis, anaerobic and mixed antibacterial infections.
 [13, 14] It’s a prodrug that is activated by reduction of the 
nitro group by susceptible organisms 
[15] and acts by getting reduced to a product which interacts with DNA to 
cause a loss of helical DNA structure and strand breakage resulting in inhibition of protein synthesis and cell 
death in susceptible organism.
 [16] Side effects rarely are severe enough to discontinue therapy. Common side 
effects are headache, nausea, dry mouth, and a metallic taste. Vomiting, diarrhoea, and abdominal distress are 
experienced occasionally. The most dangerous side effects are Neurotoxic side effects (e.g., dizziness, vertigo, 
and very rarely, encephalopathy, convulsions, incoordination, and ataxia) mandate metronidazole 
discontinuation. The drug also should be withdrawn if numbness or paresthesias occur. Urticaria, flushing, and 
pruritus are indications of drug sensitivity. It rarely causes toxic epidermal necrolysis. 
[13] Metronidazole and 
other nitroimidazole-derivative, tinidazole, ornidazole, secnidazole and satranidazole have been used for a long 
time including self medication without any serious side effects. Increasing reports of FDEs caused by 
metronidazole and tinidazole are available now. 
[17, 18] Reports of FDE caused by ornidazole are also available in 
recent time. 
[19, 20] However, genital FDE on glans penis due to metronidazole occurs rarely so much so, in books 
it is not mentioned in the list of causative drugs.  
This is the case of a 22 year old male patient. He was admitted in the General Surgery ward of North Eastern 
Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS), Shillong, Meghalaya for 
Appendicitis. He was administered Metronidazole infusion 500 mg IV 12 Hourly, Inj. Cefotaxime 1 gm IV/IM 
12 Hourly, Inj. Ranitidine 50 mg IV/IM 8 Hourly, inj. Metoclopramide IM/IV stat & sos basis and IV fluids. He 
developed itching in some part of the body including glans penis on the very first day of above treatment and 
noticed erosion over the glans penis on 2nd day. The case was referred to Dermatology department next day. On 
examination, vitals were stable and there was no pus discharge. He was nondiabetic and he denied history of any 
sexual exposure. There was single superficial non-tender ulceration with erythematous halo over the glans 
without lymphadenopathy.  
 
The case was provisionally diagnosed as FDE due to metronidazole considering the previous history of pruritus 
and FDE secondary to metronidazole and patient was advised to stop IV Metronidazole. Our provisional 
diagnosis was supported by literature review which revealed the presence of fixed drug eruption due to 
metronidazole. 
Complete blood count, random blood sugar and serum electrolyte showed within normal limits. The patient was 
advised to continue with IV fluid, Inj. Cefotaxime, Tab Paracetamol sos and Tab Ranitidine 50 mg 12 hourly.  
Wahlang JB et al. / International Journal of Pharma Sciences and Research (IJPSR)
ISSN : 0975-9492 Vol 3 No 3 March 2012 332The FDE was managed with Tab. Prednisolone 30 mg/day tapered over 10 days, along with Tab. Ranitidine, 
Tab. Cetirizine 10 mg 1 tablet HS and Fusidic acid+Betamethasone cream. 
Follow up on the 4th day of treatment, there was no pruritus, erythematous ulceration was subsiding. On the 
11th day no lesion was seen except a hyperpigmented area. Patient and his attendants were counseled not to 
consume metronidazole in future. The assessment showed probable (Score - 5), moderate (level - 4) and 
preventable type of ADR as per Naranjo algorithm, 
[10] Hartwig scale 
[11] and modified Schumock and Thornton 
Scale 
[12] respectively.  
DISCUSSION:  
 
The exact pathogenesis of FDE is unknown, although antibodies, antibody-dependent cell-mediated 
cytotoxicity, and serum factors have been implicated.
 [21] According to one hypothesis FDE is classified as a 
type IVc immunologic reaction because of latent cytotoxic T cells in the lesions, which may become reactivated. 
There is also an association with HLA class I antigens, suggesting that there may be a genetic predisposition to 
these reactions.
 [22] The peak incidence of FDE is 21-30 years and male:female incidence is generally equal, 
although any age/sex may be affected. Genetic predisposition to FDE appears to occur in individuals with a 
family history of diabetes mellitus, atopy, and drug allergies.
 [23] 
 
FDEs have a predilection for the glans Penis 
[8] and erosions are usually well demarcated erythematous areas 
which may be bullous and subsequently ulcerated. In one of the reports oral Metronidazole caused fixed drug 
eruptions on Penis.
 [9] In another report, FDE started on the 2
nd day in a patient administered intravenous 
metronidazole.
 [24]   FDEs due to metronidazole usually occur within 30 min to 8 hours following administration 
of drug.
 [19] In one of the study, ADR started after 8 hour of Metronidazole,
 [25] and in another study reaction 
started only after 3
rd day of Re-challenge.
 [26] In our case also metronidazole was administered IV and the 
reaction started on the 1
st day onwards on penis. This early onset may be due to the IV route of the drug. Our 
patient is a 22 years male which is within the common age group of FDEs (21 to 30 years).
   
 
Laboratory findings of a patient with FDE demonstrate interface dermatitis with basal vacuolization and 
necrosis of keratinocytes, which may lead to sub-epidermal blistering in florid lesions. Lymphocytes and 
incontinent melanocytes are often found in the epidermis.
 [27] Biopsy may be one tool for the diagnosis of FDE, 
but systemic re-challenge is currently the standard method for diagnosis. 
 
CONCLUSION: 
 
We presented this case of FDE as it was detected in the initial days of starting the Dermatology OPD facilities at 
our Institute. Our Institute is the only teaching medical Institute in the state of Meghalaya, India having started 
its UG and PG medical teaching programmes in the year 2008 and 2009 respectively. This is the first ever ADR 
reporting literature from our Institute and also from the state of Meghalaya, India. We want to make a point here 
is that the state of Meghalaya in India is having an ethnic tribal population of 85.9% as per the Census of India 
2001. Therefore, ADR and related data from the Hospitals of this region may be important from the point of 
view of identifying new information about hazards associated with medicines towards promoting safer use of 
medicines. A vibrant Pharmacovigilance activity is the need of the hour in this region.  
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